<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:59:31 -0700</creation_date>
  <update_date>2013-05-27 11:16:11 -0600</update_date>
  <accession>HMDBP01795</accession>
  <secondary_accessions>
    <accession>7152</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Acid beta-glucosidase</synonym>
    <synonym>Alglucerase</synonym>
    <synonym>Beta-glucocerebrosidase</synonym>
    <synonym>D-glucosyl-N-acylsphingosine glucohydrolase</synonym>
    <synonym>Imiglucerase</synonym>
  </synonyms>
  <gene_name>GBA</gene_name>
  <general_function>Involved in catalytic activity</general_function>
  <specific_function></specific_function>
  <pathways>
    <pathway>
      <name>Other glycan degradation</name>
      <smpdb_id/>
      <kegg_map_id>map00511</kegg_map_id>
    </pathway>
    <pathway>
      <name>sphingolipid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00600</kegg_map_id>
    </pathway>
    <pathway>
      <name>Lysosome</name>
      <smpdb_id/>
      <kegg_map_id>map04142</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00596</accession>
      <name>Glucosylsphingosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00055</accession>
      <name>Cellobiose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00122</accession>
      <name>D-Glucose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00140</accession>
      <name>Glucosylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00516</accession>
      <name>Beta-D-Glucose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03345</accession>
      <name>Alpha-D-Glucose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04947</accession>
      <name>Ceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04948</accession>
      <name>Ceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04949</accession>
      <name>Ceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04950</accession>
      <name>Ceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04951</accession>
      <name>Ceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04952</accession>
      <name>Ceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04953</accession>
      <name>Cer(d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04954</accession>
      <name>Cer(d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04955</accession>
      <name>Cer(d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04956</accession>
      <name>Ceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04957</accession>
      <name>Ceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04969</accession>
      <name>Glucosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04970</accession>
      <name>Glucosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04971</accession>
      <name>Glucosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04972</accession>
      <name>Glucosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04973</accession>
      <name>Glucosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04974</accession>
      <name>Glucosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04975</accession>
      <name>Glucosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04976</accession>
      <name>Glucosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04977</accession>
      <name>Glucosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04979</accession>
      <name>Glucosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06944</accession>
      <name>1,4-beta-D-Glucan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00024</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04832</accession>
      <name>Galabiosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04833</accession>
      <name>Galabiosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04834</accession>
      <name>Galabiosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04835</accession>
      <name>Galabiosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04836</accession>
      <name>Galabiosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04837</accession>
      <name>Galabiosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04838</accession>
      <name>Galabiosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04839</accession>
      <name>Galabiosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04840</accession>
      <name>Galabiosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04841</accession>
      <name>Galabiosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04866</accession>
      <name>Lactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04872</accession>
      <name>Lactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04873</accession>
      <name>Lactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04874</accession>
      <name>Lactosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04876</accession>
      <name>Lactosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04877</accession>
      <name>Trihexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04878</accession>
      <name>Trihexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04879</accession>
      <name>Trihexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04880</accession>
      <name>Trihexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04881</accession>
      <name>Trihexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04882</accession>
      <name>Trihexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04883</accession>
      <name>Trihexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04884</accession>
      <name>Trihexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04886</accession>
      <name>Trihexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04887</accession>
      <name>Trihexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04958</accession>
      <name>Tetrahexosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04959</accession>
      <name>Tetrahexosylceramide (d18:1/9Z-18:1)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04960</accession>
      <name>Tetrahexosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04961</accession>
      <name>Tetrahexosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04962</accession>
      <name>Tetrahexosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04963</accession>
      <name>Tetrahexosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04964</accession>
      <name>Tetrahexosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04965</accession>
      <name>Tetrahexosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04966</accession>
      <name>Tetrahexosylceramide (d18:1/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04967</accession>
      <name>Tetrahexosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04968</accession>
      <name>Tetrahexosylceramide (d18:1/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04978</accession>
      <name>Glucosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06750</accession>
      <name>Lactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06752</accession>
      <name>Dihydroceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10697</accession>
      <name>Cer(t18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10708</accession>
      <name>Galactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10709</accession>
      <name>Galactosylceramide (d18:1/18:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10710</accession>
      <name>Galactosylceramide (d18:1/20:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10711</accession>
      <name>Galactosylceramide (d18:1/22:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10712</accession>
      <name>Galactosylceramide (d18:1/24:1(15Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10713</accession>
      <name>Galactosylceramide (d18:1/26:1(17Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB10714</accession>
      <name>Galactosylceramide (d18:1/18:1(9Z)) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB11591</accession>
      <name>Lactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11592</accession>
      <name>Lactosyceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11594</accession>
      <name>Lactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11595</accession>
      <name>Lactosylceramide (d18:1/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12237</accession>
      <name>Inositol-P-ceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12256</accession>
      <name>Mannosyl-diinositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12257</accession>
      <name>Mannosyl-inositol-phosphorylceramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12311</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12312</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12313</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12314</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12315</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12316</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12317</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12318</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12319</accession>
      <name>3-O-Sulfogalactosylceramide (d18:1/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12320</accession>
      <name>Galactosylceramide (d18:1/12:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB12321</accession>
      <name>Galactosylceramide (d18:1/14:0) </name>
    </metabolite>
    <metabolite>
      <accession>HMDB00950</accession>
      <name>Cer(d18:1/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11758</accession>
      <name>Cer(d18:0/12:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11759</accession>
      <name>Cer(d18:0/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11760</accession>
      <name>Cer(d18:0/16:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11761</accession>
      <name>Cer(d18:0/18:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11762</accession>
      <name>Cer(d18:0/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11763</accession>
      <name>Cer(d18:0/18:1(9Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11764</accession>
      <name>Cer(d18:0/20:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11765</accession>
      <name>Cer(d18:0/22:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11766</accession>
      <name>Cer(d18:0/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11767</accession>
      <name>Cer(d18:0/23:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11768</accession>
      <name>Cer(d18:0/24:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11769</accession>
      <name>Cer(d18:0/24:1(15Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11770</accession>
      <name>Cer(d18:0/25:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11771</accession>
      <name>Cer(d18:0/26:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11772</accession>
      <name>Cer(d18:0/26:1(17Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11773</accession>
      <name>Cer(d18:1/14:0)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11774</accession>
      <name>Cer(d18:1/18:1(11Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11775</accession>
      <name>Cer(d18:1/22:1(13Z))</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01586</accession>
      <name>Glucose 1-phosphate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on glycosyl bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, hydrolyzing o-glycosyl compounds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>glucosylceramidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>carbohydrate metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular component organization at cellular level</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>organelle organization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>vacuole organization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lysosome organization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>primary metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>membrane lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>sphingolipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>vacuole</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>lytic vacuole</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>lysosome</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>lysosomal lumen</description>
      <go_id>GO:0043202</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>lysosomal membrane</description>
      <go_id>GO:0005765</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cation binding</description>
      <go_id>GO:0043169</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>glucosylceramidase activity</description>
      <go_id>GO:0004348</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>receptor binding</description>
      <go_id>GO:0005102</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>carbohydrate metabolic process</description>
      <go_id>GO:0005975</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell death</description>
      <go_id>GO:0008219</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to tumor necrosis factor</description>
      <go_id>GO:0071356</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>ceramide biosynthetic process</description>
      <go_id>GO:0046513</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>glucosylceramide catabolic process</description>
      <go_id>GO:0006680</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>lysosome organization</description>
      <go_id>GO:0007040</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of inflammatory response</description>
      <go_id>GO:0050728</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of interleukin-6 production</description>
      <go_id>GO:0032715</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of MAP kinase activity</description>
      <go_id>GO:0043407</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phospholipid metabolic process</description>
      <go_id>GO:0006644</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of protein dephosphorylation</description>
      <go_id>GO:0035307</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>sphingosine biosynthetic process</description>
      <go_id>GO:0046512</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>termination of signal transduction</description>
      <go_id>GO:0023021</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Lysosome membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
    <subcellular_location>Lumenal side</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>1</chromosome_location>
    <locus>1q21</locus>
    <gene_sequence>&gt;1611 bp
ATGGAGTTTTCAAGTCCTTCCAGAGAGGAATGTCCCAAGCCTTTGAGTAGGGTAAGCATC
ATGGCTGGCAGCCTCACAGGATTGCTTCTACTTCAGGCAGTGTCGTGGGCATCAGGTGCC
CGCCCCTGCATCCCTAAAAGCTTCGGCTACAGCTCGGTGGTGTGTGTCTGCAATGCCACA
TACTGTGACTCCTTTGACCCCCCGACCTTTCCTGCCCTTGGTACCTTCAGCCGCTATGAG
AGTACACGCAGTGGGCGACGGATGGAGCTGAGTATGGGGCCCATCCAGGCTAATCACACG
GGCACAGGCCTGCTACTGACCCTGCAGCCAGAACAGAAGTTCCAGAAAGTGAAGGGATTT
GGAGGGGCCATGACAGATGCTGCTGCTCTCAACATCCTTGCCCTGTCACCCCCTGCCCAA
AATTTGCTACTTAAATCGTACTTCTCTGAAGAAGGAATCGGATATAACATCATCCGGGTA
CCCATGGCCAGCTGTGACTTCTCCATCCGCACCTACACCTATGCAGACACCCCTGATGAT
TTCCAGTTGCACAACTTCAGCCTCCCAGAGGAAGATACCAAGCTCAAGATACCCCTGATT
CACCGAGCCCTGCAGTTGGCCCAGCGTCCCGTTTCACTCCTTGCCAGCCCCTGGACATCA
CCCACTTGGCTCAAGACCAATGGAGCGGTGAATGGGAAGGGGTCACTCAAGGGACAGCCC
GGAGACATCTACCACCAGACCTGGGCCAGATACTTTGTGAAGTTCCTGGATGCCTATGCT
GAGCACAAGTTACAGTTCTGGGCAGTGACAGCTGAAAATGAGCCTTCTGCTGGGCTGTTG
AGTGGATACCCCTTCCAGTGCCTGGGCTTCACCCCTGAACATCAGCGAGACTTCATTGCC
CGTGACCTAGGTCCTACCCTCGCCAACAGTACTCACCACAATGTCCGCCTACTCATGCTG
GATGACCAACGCTTGCTGCTGCCCCACTGGGCAAAGGTGGTACTGACAGACCCAGAAGCA
GCTAAATATGTTCATGGCATTGCTGTACATTGGTACCTGGACTTTCTGGCTCCAGCCAAA
GCCACCCTAGGGGAGACACACCGCCTGTTCCCCAACACCATGCTCTTTGCCTCAGAGGCC
TGTGTGGGCTCCAAGTTCTGGGAGCAGAGTGTGCGGCTAGGCTCCTGGGATCGAGGGATG
CAGTACAGCCACAGCATCATCACGAACCTCCTGTACCATGTGGTCGGCTGGACCGACTGG
AACCTTGCCCTGAACCCCGAAGGAGGACCCAATTGGGTGCGTAACTTTGTCGACAGTCCC
ATCATTGTAGACATCACCAAGGACACGTTTTACAAACAGCCCATGTTCTACCACCTTGGC
CACTTCAGCAAGTTCATTCCTGAGGGCTCCCAGAGAGTGGGGCTGGTTGCCAGTCAGAAG
AACGACCTGGACGCAGTGGCACTGATGCATCCCGATGGCTCTGCTGTTGTGGTCGTGCTA
AACCGCTCCTCTAAGGATGTGCCTCTTACCATCAAGGATCCTGCTGTGGGCTTCCTGGAG
ACAATCTCACCTGGCTACTCCATTCACACCTACCTGTGGCGTCGCCAGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>536</residue_number>
    <molecular_weight>59715.745</molecular_weight>
    <theoretical_pi>7.601</theoretical_pi>
    <pfams>
      <pfam>
        <name>Glyco_hydro_30</name>
        <pfam_id>PF02055</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Glucosylceramidase
MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNAT
YCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGF
GGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDD
FQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQP
GDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIA
RDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAK
ATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDW
NLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQK
NDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ</protein_sequence>
  </protein_properties>
  <genbank_protein_id>2564914</genbank_protein_id>
  <uniprot_id>P04062</uniprot_id>
  <uniprot_name>GLCM_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1OGS</pdb_id>
    <pdb_id>1Y7V</pdb_id>
    <pdb_id>2F61</pdb_id>
    <pdb_id>2J25</pdb_id>
    <pdb_id>2NSX</pdb_id>
    <pdb_id>2NT0</pdb_id>
    <pdb_id>2NT1</pdb_id>
    <pdb_id>2V3D</pdb_id>
    <pdb_id>2V3E</pdb_id>
    <pdb_id>2V3F</pdb_id>
    <pdb_id>2VT0</pdb_id>
    <pdb_id>2WCG</pdb_id>
    <pdb_id>2WKL</pdb_id>
    <pdb_id>2XWD</pdb_id>
    <pdb_id>2XWE</pdb_id>
    <pdb_id>3GXD</pdb_id>
    <pdb_id>3GXF</pdb_id>
    <pdb_id>3GXI</pdb_id>
    <pdb_id>3GXM</pdb_id>
    <pdb_id>3KE0</pdb_id>
    <pdb_id>3KEH</pdb_id>
    <pdb_id>3RIK</pdb_id>
    <pdb_id>3RIL</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AF023268</genbank_gene_id>
  <genecard_id>GBA</genecard_id>
  <geneatlas_id>GBA</geneatlas_id>
  <hgnc_id>HGNC:4177</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Sorge J, West C, Westwood B, Beutler E: Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7289-93.</reference_text>
      <pubmed_id>3864160</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tsuji S, Choudary PV, Martin BM, Winfield S, Barranger JA, Ginns EI: Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J Biol Chem. 1986 Jan 5;261(1):50-3.</reference_text>
      <pubmed_id>3001061</pubmed_id>
    </reference>
    <reference>
      <reference_text>Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E: The human glucocerebrosidase gene and pseudogene: structure and evolution.  Genomics. 1989 Jan;4(1):87-96.</reference_text>
      <pubmed_id>2914709</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, West C, Gelbart T: Polymorphisms in the human glucocerebrosidase gene.  Genomics. 1992 Apr;12(4):795-800.</reference_text>
      <pubmed_id>1572652</pubmed_id>
    </reference>
    <reference>
      <reference_text>Imai K, Nakamura M, Yamada M, Asano A, Yokoyama S, Tsuji S, Ginns EI: A novel transcript from a pseudogene for human glucocerebrosidase in non-Gaucher disease cells. Gene. 1993 Dec 22;136(1-2):365-8.</reference_text>
      <pubmed_id>8294033</pubmed_id>
    </reference>
    <reference>
      <reference_text>Winfield SL, Tayebi N, Martin BM, Ginns EI, Sidransky E: Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res. 1997 Oct;7(10):1020-6.</reference_text>
      <pubmed_id>9331372</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1.  Nature. 2006 May 18;441(7091):315-21.</reference_text>
      <pubmed_id>16710414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Reiner O, Wigderson M, Horowitz M: Structural analysis of the human glucocerebrosidase genes.  DNA. 1988 Mar;7(2):107-16.</reference_text>
      <pubmed_id>3359914</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sorge JA, West C, Kuhl W, Treger L, Beutler E: The human glucocerebrosidase gene has two functional ATG initiator codons.  Am J Hum Genet. 1987 Dec;41(6):1016-24.</reference_text>
      <pubmed_id>3687939</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ginns EI, Choudary PV, Martin BM, Winfield S, Stubblefield B, Mayor J, Merkle-Lehman D, Murray GJ, Bowers LA, Barranger JA: Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system. Biochem Biophys Res Commun. 1984 Sep 17;123(2):574-80.</reference_text>
      <pubmed_id>6091633</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI: Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2349-52.</reference_text>
      <pubmed_id>3353383</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dinur T, Osiecki KM, Legler G, Gatt S, Desnick RJ, Grabowski GA: Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1660-4.</reference_text>
      <pubmed_id>3456607</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miao S, McCarter JD, Grace ME, Grabowski GA, Aebersold R, Withers SG: Identification of Glu340 as the active-site nucleophile in human glucocerebrosidase by use of electrospray tandem mass spectrometry. J Biol Chem. 1994 Apr 15;269(15):10975-8.</reference_text>
      <pubmed_id>7908905</pubmed_id>
    </reference>
    <reference>
      <reference_text>Salvioli R, Tatti M, Ciaffoni F, Vaccaro AM: Further studies on the reconstitution of glucosylceramidase activity by Sap C and anionic phospholipids. FEBS Lett. 2000 Apr 21;472(1):17-21.</reference_text>
      <pubmed_id>10781797</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.</reference_text>
      <pubmed_id>12754519</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schroder B, Wrocklage C, Pan C, Jager R, Kosters B, Schafer H, Elsasser HP, Mann M, Hasilik A: Integral and associated lysosomal membrane proteins.  Traffic. 2007 Dec;8(12):1676-86. Epub 2007 Sep 26.</reference_text>
      <pubmed_id>17897319</pubmed_id>
    </reference>
    <reference>
      <reference_text>Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW: Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009 Jul;132(Pt 7):1783-94. Epub 2009 Mar 13.</reference_text>
      <pubmed_id>19286695</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61.</reference_text>
      <pubmed_id>19159218</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL: X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 2003 Jul;4(7):704-9.</reference_text>
      <pubmed_id>12792654</pubmed_id>
    </reference>
    <reference>
      <reference_text>Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, Kelly JW, Futerman AH, Sussman JL: X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem. 2005 Jun 24;280(25):23815-9. Epub 2005 Apr 6.</reference_text>
      <pubmed_id>15817452</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liou B, Kazimierczuk A, Zhang M, Scott CR, Hegde RS, Grabowski GA: Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem. 2006 Feb 17;281(7):4242-53. Epub 2005 Nov 17.</reference_text>
      <pubmed_id>16293621</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brumshtein B, Wormald MR, Silman I, Futerman AH, Sussman JL: Structural comparison of differently glycosylated forms of acid-beta-glucosidase, the defective enzyme in Gaucher disease. Acta Crystallogr D Biol Crystallogr. 2006 Dec;62(Pt 12):1458-65. Epub 2006       Nov 23.</reference_text>
      <pubmed_id>17139081</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA: Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2007 Feb;3(2):101-7. Epub 2006 Dec 24.</reference_text>
      <pubmed_id>17187079</pubmed_id>
    </reference>
    <reference>
      <reference_text>Horowitz M, Zimran A: Mutations causing Gaucher disease.  Hum Mutat. 1994;3(1):1-11.</reference_text>
      <pubmed_id>8118460</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Gelbart T: Glucocerebrosidase (Gaucher disease).  Hum Mutat. 1996;8(3):207-13.</reference_text>
      <pubmed_id>8889578</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tayebi N, Stone DL, Sidransky E: Type 2 gaucher disease: an expanding phenotype.  Mol Genet Metab. 1999 Oct;68(2):209-19.</reference_text>
      <pubmed_id>10527671</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E: Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.  Hum Mutat. 2000;15(2):181-8.</reference_text>
      <pubmed_id>10649495</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Gelbart T: Gaucher disease associated with a unique KpnI restriction site: identification of the amino-acid substitution. Ann Hum Genet. 1990 May;54(Pt 2):149-53.</reference_text>
      <pubmed_id>1974409</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hong CM, Ohashi T, Yu XJ, Weiler S, Barranger JA: Sequence of two alleles responsible for Gaucher disease.  DNA Cell Biol. 1990 May;9(4):233-41.</reference_text>
      <pubmed_id>1972019</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Gelbart T, West C: Identification of six new Gaucher disease mutations.  Genomics. 1993 Jan;15(1):203-5.</reference_text>
      <pubmed_id>8432537</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Wei C, Applegarth DA, McGillivray BC: DNA analysis of an uncommon missense mutation in a Gaucher disease patient of Jewish-Polish-Russian descent. Am J Med Genet. 1994 Jun 1;51(2):156-60.</reference_text>
      <pubmed_id>7916532</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Gelbart T: Two new Gaucher disease mutations.  Hum Genet. 1994 Feb;93(2):209-10.</reference_text>
      <pubmed_id>8112750</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tuteja R, Tuteja N, Lilliu F, Bembi B, Galanello R, Cao A, Baralle FE: Y418C: a novel mutation in exon 9 of the glucocerebrosidase gene of a patient with Gaucher disease creates a new Bgl I site. Hum Genet. 1994 Sep;94(3):314-5.</reference_text>
      <pubmed_id>8076951</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Demina A, Gelbart T: Glucocerebrosidase mutations in Gaucher disease.  Mol Med. 1994 Nov;1(1):82-92.</reference_text>
      <pubmed_id>8790604</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cormand B, Vilageliu L, Burguera JM, Balcells S, Gonzalez-Duarte R, Grinberg D, Chabas A: Gaucher disease in Spanish patients: analysis of eight mutations.  Hum Mutat. 1995;5(4):303-9.</reference_text>
      <pubmed_id>7627184</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Wei C: Identification of a new mutation (P178S) in an African-American patient with type 2 Gaucher disease. Hum Mutat. 1995;5(4):345-7.</reference_text>
      <pubmed_id>7627192</pubmed_id>
    </reference>
    <reference>
      <reference_text>Morar B, Lane AB: The molecular characterization of Gaucher disease in South Africa.  Clin Genet. 1996 Aug;50(2):78-84.</reference_text>
      <pubmed_id>8937765</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim JW, Liou BB, Lai MY, Ponce E, Grabowski GA: Gaucher disease: identification of three new mutations in the Korean and Chinese (Taiwanese) populations. Hum Mutat. 1996;7(3):214-8.</reference_text>
      <pubmed_id>8829654</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cormand B, Vilageliu L, Balcells S, Gonzalez-Duarte R, Chabas A, Grinberg D: Two novel (1098insA and Y313H) and one rare (R359Q) mutations detected in exon 8 of the beta-glucocerebrosidase gene in Gaucher's disease patients. Hum Mutat. 1996;7(3):272-4.</reference_text>
      <pubmed_id>8829663</pubmed_id>
    </reference>
    <reference>
      <reference_text>Amaral O, Pinto E, Fortuna M, Lacerda L, Sa Miranda MC: Type 1 Gaucher disease: identification of N396T and prevalence of glucocerebrosidase mutations in the Portuguese. Hum Mutat. 1996;8(3):280-1.</reference_text>
      <pubmed_id>8889591</pubmed_id>
    </reference>
    <reference>
      <reference_text>Seeman PJ, Finckh U, Hoppner J, Lakner V, Liebisch I, Grau G, Rolfs A: Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease. Neurology. 1996 Apr;46(4):1102-7.</reference_text>
      <pubmed_id>8780099</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cormand B, Grinberg D, Gort L, Fiumara A, Barone R, Vilageliu L, Chabas A: Two new mild homozygous mutations in Gaucher disease patients: clinical signs and biochemical analyses. Am J Med Genet. 1997 Jun 27;70(4):437-43.</reference_text>
      <pubmed_id>9182788</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Humphries ML, Shi H: Identification of two novel and four uncommon missense mutations among chinese Gaucher disease patients. Am J Med Genet. 1997 Aug 8;71(2):172-8.</reference_text>
      <pubmed_id>9217217</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hatton CE, Cooper A, Whitehouse C, Wraith JE: Mutation analysis in 46 British and Irish patients with Gaucher's disease.  Arch Dis Child. 1997 Jul;77(1):17-22.</reference_text>
      <pubmed_id>9279145</pubmed_id>
    </reference>
    <reference>
      <reference_text>Grace ME, Desnick RJ, Pastores GM: Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients. J Clin Invest. 1997 May 15;99(10):2530-7.</reference_text>
      <pubmed_id>9153297</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y: Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis. 1997 Mar;20(1):67-73.</reference_text>
      <pubmed_id>9061570</pubmed_id>
    </reference>
    <reference>
      <reference_text>Uyama E, Uchino M, Ida H, Eto Y, Owada M: D409H/D409H genotype in Gaucher-like disease.  J Med Genet. 1997 Feb;34(2):175.</reference_text>
      <pubmed_id>9040001</pubmed_id>
    </reference>
    <reference>
      <reference_text>Demina A, Beutler E: Six new Gaucher disease mutations.  Acta Haematol. 1998;99(2):80-2.</reference_text>
      <pubmed_id>9554454</pubmed_id>
    </reference>
    <reference>
      <reference_text>Germain DP, Puech JP, Caillaud C, Kahn A, Poenaru L: Exhaustive screening of the acid beta-glucosidase gene, by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype/phenotype correlations in Gaucher disease. Am J Hum Genet. 1998 Aug;63(2):415-27.</reference_text>
      <pubmed_id>9683600</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Humphries ML, Ben-Yoseph Y: Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient. Am J Med Genet. 1998 Jun 16;78(1):92-3.</reference_text>
      <pubmed_id>9637431</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beutler E, Gelbart T: Hematologically important mutations: Gaucher disease.  Blood Cells Mol Dis. 1998 Mar;24(1):2-8.</reference_text>
      <pubmed_id>9516376</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sinclair G, Choy FY, Humphries L: A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Blood Cells Mol Dis. 1998 Dec;24(4):420-7.</reference_text>
      <pubmed_id>9851895</pubmed_id>
    </reference>
    <reference>
      <reference_text>Parenti G, Filocamo M, Titomanlio L, Rizzolo G, Silvestro E, Perretti A, Gatti R, Andria G: A novel mutation of the beta-glucocerebrosidase gene associated with neurologic manifestations in three sibs. Clin Genet. 1998 Apr;53(4):281-5.</reference_text>
      <pubmed_id>9650766</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cormand B, Grinberg D, Gort L, Chabas A, Vilageliu L: Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat. 1998;11(4):295-305.</reference_text>
      <pubmed_id>9554746</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Humphries ML, Ben-Yoseph Y: A novel mutation (V191G) in a German-British type 1 Gaucher disease patient. Mutations in brief no. 131. Online. Hum Mutat. 1998;11(5):411-2.</reference_text>
      <pubmed_id>10206680</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wasserstein MP, Martignetti JA, Zeitlin R, Lumerman H, Solomon M, Grace ME, Desnick RJ: Type 1 Gaucher disease presenting with extensive mandibular lytic lesions: identification and expression of a novel acid beta-glucosidase mutation. Am J Med Genet. 1999 Jun 4;84(4):334-9.</reference_text>
      <pubmed_id>10340647</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choy FY, Wong K, Shi HP: Glucocerebrosidase mutations among Chinese neuronopathic and non-neuronopathic Gaucher disease patients. Am J Med Genet. 1999 Jun 11;84(5):484-6.</reference_text>
      <pubmed_id>10360404</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hodanov inverted question mark K, Hrebicek M, Cervenkov inverted question mark M, Mr inverted question markzov inverted question mark L, Veprekov inverted question mark L, Zemen J: Analysis of the beta-glucocerebrosidase gene in Czech and Slovak Gaucher patients: mutation profile and description of six novel mutant alleles. Blood Cells Mol Dis. 1999 Oct-Dec;25(5-6):287-98.</reference_text>
      <pubmed_id>10744424</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stone DL, van Diggelen OP, de Klerk JB, Gaillard JL, Niermeijer MF, Willemsen R, Tayebi N, Sidransky E: Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease? Eur J Hum Genet. 1999 May-Jun;7(4):505-9.</reference_text>
      <pubmed_id>10352942</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sarria AJ, Giraldo P, Perez-Calvo JI, Pocovi M: Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55;1342G&amp;gt;C]] in Spanish Gaucher disease patients. Mutation in brief no. 251. Online. Hum Mutat. 1999;14(1):88.</reference_text>
      <pubmed_id>10447266</pubmed_id>
    </reference>
    <reference>
      <reference_text>Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000 Jun;66(6):1777-86. Epub 2000 May 4.</reference_text>
      <pubmed_id>10796875</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bodamer OA, Church HJ, Cooper A, Wraith JE, Scott CR, Scaglia F: Variant Gaucher disease characterized by dysmorphic features, absence of cardiovascular involvement, laryngospasm, and compound heterozygosity for a novel mutation (D409H/C16S). Am J Med Genet. 2002 May 15;109(4):328-31.</reference_text>
      <pubmed_id>11992489</pubmed_id>
    </reference>
    <reference>
      <reference_text>Orvisky E, Park JK, Parker A, Walker JM, Martin BM, Stubblefield BK, Uyama E, Tayebi N, Sidransky E: The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease. Hum Mutat. 2002 Apr;19(4):458-9.</reference_text>
      <pubmed_id>11933202</pubmed_id>
    </reference>
    <reference>
      <reference_text>Filocamo M, Mazzotti R, Stroppiano M, Seri M, Giona F, Parenti G, Regis S, Corsolini F, Zoboli S, Gatti R: Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian gaucher patients. Hum Mutat. 2002 Sep;20(3):234-5.</reference_text>
      <pubmed_id>12204005</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, Martini C, Gioulis M, Pittis MG, Capus L: Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology. 2003 Jul 8;61(1):99-101.</reference_text>
      <pubmed_id>12847165</pubmed_id>
    </reference>
    <reference>
      <reference_text>Church HJ, Cooper A, Stewart F, Thornton CM, Wraith JE: Homozygous loss of a cysteine residue in the glucocerebrosidase gene results in Gaucher's disease with a hydropic phenotype. Eur J Hum Genet. 2004 Nov;12(11):975-8.</reference_text>
      <pubmed_id>15292921</pubmed_id>
    </reference>
    <reference>
      <reference_text>Salvioli R, Tatti M, Scarpa S, Moavero SM, Ciaffoni F, Felicetti F, Kaneski CR, Brady RO, Vaccaro AM: The N370S (Asn370--&amp;gt;Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. Biochem J. 2005 Aug 15;390(Pt 1):95-103.</reference_text>
      <pubmed_id>15826241</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miocic S, Filocamo M, Dominissini S, Montalvo AL, Vlahovicek K, Deganuto M, Mazzotti R, Cariati R, Bembi B, Pittis MG: Identification and functional characterization of five novel mutant alleles in 58 Italian patients with Gaucher disease type 1. Hum Mutat. 2005 Jan;25(1):100.</reference_text>
      <pubmed_id>15605411</pubmed_id>
    </reference>
    <reference>
      <reference_text>Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology. 2005 Nov 8;65(9):1460-1. Epub 2005 Sep 7.</reference_text>
      <pubmed_id>16148263</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tan EK, Tong J, Fook-Chong S, Yih Y, Wong MC, Pavanni R, Zhao Y: Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol. 2007 Jul;64(7):1056-8.</reference_text>
      <pubmed_id>17620502</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mata IF, Samii A, Schneer SH, Roberts JW, Griffith A, Leis BC, Schellenberg GD, Sidransky E, Bird TD, Leverenz JB, Tsuang D, Zabetian CP: Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.  Arch Neurol. 2008 Mar;65(3):379-82.</reference_text>
      <pubmed_id>18332251</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.</reference_text>
      <pubmed_id>19846850</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
  </metabolite_references>
</protein>
